Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,652 total articles
Noble Corp PLC President and CEO Robert W. Eifler sold 100,000 company shares on March 18, 2026, for $4.6 million in two tranches executed under a Rule 10b5-1 plan. The company posted mixed fourth-quarter 2025 results, with an EPS shortfall against expectations but revenue above forecasts. External analysis flags the stock as overvalued relative to…
Deborah Stein, a director at RB Global INC (NYSE: RBA), bought 400 shares on March 18, 2026, for $98.74 each, a total outlay of $39,496. The transaction raised her direct holdings to 1,400 shares. The purchase price exceeded the prevailing share price of $95.84, while InvestingPro’s Fair Value assessment indicates the stock remains undervalued. Sep…
Stoke Therapeutics Chief Financial Officer Thomas Leggett sold 5,378 shares of company stock on March 17 and 18, 2026, in a series of transactions that generated $147,144. The disposition was reported as an issuer-mandated sale to satisfy tax withholding tied to vested restricted stock units. The trades come amid mixed signals for the company: stro…
Paul A. Maleh, president and CEO of CRA International, sold 7,182 shares on March 17, 2026, for a total of $1.16 million under a Rule 10b5-1 trading plan. The company reported record revenue for the fourth quarter and full year of 2025, topping revenue estimates but narrowly missing EPS forecasts. CRAI shares traded near their 52-week low amid thos…
Jason Hoitt, chief patient officer at Stoke Therapeutics (NASDAQ: STOK), sold 3,712 shares of common stock on March 17-18, 2026 to satisfy tax withholding obligations tied to restricted stock unit vesting. The transactions totaled $119,310 and leave Hoitt with 10,276 shares. The company also disclosed executive compensation details and updated clin…
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, sold 8,995 shares of company stock across transactions on March 17 and 18, 2026, generating approximately $285,900. The sales were disclosed as mandated transactions to satisfy tax withholding tied to restricted stock unit vesting and settlement. Separately, Stoke's boar…
ServiceTitan Chief Executive Officer Ara Mahdessian sold $159,874 of Class A Common Stock in multiple transactions on March 18, 2026, and converted 2,289 Class B shares into Class A stock. The stock has faced notable declines recently even as the company posted better-than-expected fourth-quarter results and analysts adjusted earnings and price tar…
Medpace Holdings President Jesse J. Geiger sold 31,707 shares on March 17, 2026, generating roughly $14.44 million. The transaction accompanied an exercise of options for the same number of shares at $138.87, which vested on February 15, 2026. Recent analyst activity has reflected evolving sentiment on Medpace's valuation and market position.
Enliven Therapeutics Chief Medical Officer Helen Louise Collins sold 5,000 shares on March 17, 2026, and exercised options to acquire 5,000 additional shares the same day. The stock has risen since the sale and Enliven reported positive initial Phase 1b results for ELVN-001 in chronic myeloid leukemia, while also appointing Scott Garland to its boa…
Andrew H. Rubenstein, CEO and President of Accel Entertainment, sold 3,938 shares of Class A-1 Common Stock on March 17, 2026, for roughly $44,223. The transaction occurred as the company reported robust fourth-quarter 2025 results and as an analyst firm raised its price target while maintaining a Market Outperform rating. Valuation metrics cited i…
Alaleh Nouri, Executive Vice President and CLO at PROCEPT BioRobotics Corp, sold 5,363 shares of company stock on March 19, 2026, for approximately $139,230 under a Rule 10b5-1 trading plan. The transaction occurred while shares trade at $25.68, down 56% over the past year. The company recently launched its HYDROS Robotic System in the U.K., added …
ServiceTitan, Inc. (TTAN) reported that Director and President Vahe Kuzoyan sold 3,221 shares of Class A common stock on March 18, 2026, for a total of $224,984. The trades were executed at an average price of $69.86, with individual transactions ranging from $68.33 to $74.16. On the same day Kuzoyan converted an equal number of Class B shares into…
Leonard M. Tannenbaum, a director and ten percent owner of Advanced Flower Capital Inc. (NASDAQ:AFCG), bought 151,200 shares of the company's common stock in two transactions on March 18 and March 19, 2026, at $2.59 per share for a total of $391608. The purchases leave him with more than 6.19 million shares directly and additional indirect holdings…
Richard Page Howard, a trustee of North European Oil Royalty Trust (NRT), sold 25,000 units of the trust on March 17, 2026 in two separate trades that together generated $215,601. After the sales, Howard retains direct ownership of 250,000 units. The trust currently yields 9.02% and, according to analysis cited, remains undervalued relative to its …
ServiceTitan Chief Financial Officer Sherry David sold 17,777.5 shares of Class A common stock on March 18, 2026, generating $1.24 million at an average trade price of $69.86 per share. The disposal, executed across several price tranches, was made to meet tax obligations arising from restricted stock unit vesting. The company recently reported bet…
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold 3,261 shares on March 17, 2026 under a Rule 10b5-1 plan, realizing $74,416. The company recently reported fourth-quarter 2025 results that missed consensus on both EPS and revenue and is contending with an activist campaign from a holder of roughly 7.3% of shares.
Director Mark Froimson sold 500 shares of Pacira BioSciences Inc. (NASDAQ: PCRX) on March 17, 2026, in a Form 4 filing. The trade, at $21.81 per share for $10,905, leaves Froimson with 20,136 shares. Pacira reported fourth-quarter 2025 results that missed EPS and revenue expectations, and activist investor DOMA Perpetual Capital Management LLC has …
Core Natural Resources Executive Chair and CEO James A. Brock sold 40,760 shares on March 18, 2026, receiving $4,122,874 at a weighted average price of $101.15. The sale occurred as the company's stock trades near a 52-week high, and follows a temporary shutdown at the Mountaineer II mine after an MSHA imminent danger order tied to elevated methane…
Michele O'Connor, Chief Accounting Officer at ServiceTitan, disposed of 5,159.25 shares of Class A common stock on March 18, 2026, generating roughly $360,075. The transactions - executed across a range of prices - were undertaken to satisfy tax liabilities associated with vesting restricted stock units. The moves come as the stock trades well belo…
SRB Corp, a reported ten percent holder in Safety Insurance Group Inc. (NASDAQ: SAFT), disposed of 1,199 common shares on March 17, 2026, at $73.0603 per share for a total of $87,599. The transaction was jointly reported with Plymouth Rock Co. Inc., leaving the combined filers with ownership of 1,808,806 shares. The insurer is trading at a P/E of 1…
Teresa L. Dick, Chief Administrative Officer and Executive Vice President of Diamondback Energy, sold 5,000 shares of the company's common stock on March 18, 2026, for $190.00 per share, generating $950,000 in proceeds. The transaction occurred while the stock trades close to a 52-week high, following a 38% gain over six months. Diamondback also re…
Diamondback Energy Executive Vice President and Chief Legal and Administrative Officer Matt Zmigrosky sold 4,101 shares on March 18, 2026, for a weighted average price of $190.5128, totaling $781,292, according to a Form 4 filing. The sale occurred as the stock traded close to its 52-week high and followed the company’s report of robust fourth-quar…
Fairholme Funds Inc., a roughly 10% holder of The St. Joe Company (NYSE: JOE), executed a sale of 21,100 shares on March 17, 2026, for $72.22 per share, totaling $1.52 million. The transaction occurred close to JOE's 52-week peak and follows a year of notable stock appreciation. Following the sale, Fairholme continues to directly hold more than 16 …
Ur-Energy Inc. Vice President of Finance Walle Jade purchased 107,900 common shares on March 18, 2026, at $1.39 per share for a total of $149,981. The acquisition raises Jade's direct holdings to 251,900 shares. The insider purchase occurred while the stock fell about 17% over the prior week, though it remains up roughly 56% over the past year. Rec…
Michael Alfieri, Principal Financial Officer at Aldeyra Therapeutics, purchased 5,000 shares of common stock on March 18, 2026, paying $1.42 per share for a total of $7,100. The transaction comes after a 61% decline in the stock over the previous week, with shares trading at $1.83—about 29% above Alfieri's purchase price. The company recently recei…
